Rius Medical

In Rius Medical, investor(s) shall find a founder with experience and expertise in healthcare, enterprise AI and industrial technology space.

[2] How is this opportunity innovative? [Drug Delivery] Stem cell-based therapy by Rius Medical: utilizes the unique properties of stem cells being self-renewal and differentiation to replace damaged cells with new, healthy and fully functional cells by delivering exogenous cells into multiple patients (10,000x doses). Also the Licensee entity in Denmark makes USD 1 Billion Profit after DK corporate tax each 4 years! [It is not iPSC but bone marrow derived stem cells engineered as Master cell Bank, MCB for cultured red blood cells inclusive biologic enzyme cargo] 

Beyond “Evotec and Novo Nordisk” strategic focus on stem cell-based therapies www, Rius Medical is ready via CDMO AGC Biologics, Copenhagen (EU/EEA market) and CDMO AGC Biologics, Boulder (USA Market) to provide next-generation off-the-shelf cell therapy products for clinical development and thereafter commercialisation. For example: Rare disease of metabolism, Phenylketonuria (PKU) - EU has 44,800x PKU Patients and USA has 33,600x PKU Patients that enterprise AI ensures Diagnostic alongside Therapeutics! 

The immediate focus of Rius Medical is on “enzyme cargo” red blood cells against FOUR rare diseases of metabolism and upgrade Asparaginase drug delivery against acute lymphocytic leukemia, Triple Negative Breast Cancer and pancreatic cancer. 

"Disruptive innovation" - Rius Medical, a supplier of innovation regarding “red blood cells drug delivery” witnessed Rubius Therapeutics, Erytech Pharma and SQZ Biotherapeutics failure to innovate resulting in business termination. My responsibility is to innovate! Rius Medical eliminates the side effects of hypersensitivity associated with Palynziq. And in “programming stem cells by genes over-expressions”, makes PAL enzyme affordable i.e. “43% BioMarin Palynziq”. That is, rare disease of metabolism Phenylketonuria (PKU) daily injection BioMarin Palynziq at 365x injections per year per patient to Rius Medical 4x injections per year per patient.

Are you against a partnership with Rius Medical - improve patients’ lives and transform the healthcare industry? Don't hesitate to get in touch if you are an investor seeking breakthrough solutions that radically transform patient outcomes! [denisdemarais@riusmedical.de]

In Rius Medical, investor(s) shall find a founder with experience and expertise in healthcare, enterprise AI and industrial technology space. Don't hesitate to get in touch if you are an investor seeking breakthrough solutions that radically transform patient outcomes!

[1] Turning academic discovery into cost competitive products produced at large scale, as an innovator, Rius Medical focuses on Cell therapy - the transfer of cellular materials into a patient for therapeutic purposes! That’s “enzyme cargo” red blood cells with building large-scale production facilities for protein production as “enzyme cargo”. Cells are collected from 1x donor sample to create a master cell bank (MCB). The MCB is then used as the source to create cell populations that are processed according to the demands of the specific therapy. [It is not iPSC but bone marrow derived stem cells engineered as MCB for cultured red blood cells inclusive biologic enzyme cargo]. 

Benchmark at “43% BioMarin Palynziq” where Palynziq (market-approved) is at USD 267,000 per year per patient www, the Rius Medical product on EU market is at USD 114,973 per year per patient, the product represents an annual market size in Denmark of USD 50 million; in Scandinavia of USD 199 million and in EU of USD 5 billion – same for USA.

Therapeutics: San Francisco AllCells supplies 1x CD34+ stem cells for Rius Medical engineering and culture at Longmont Colorado US CDMO AGC Biologics for OUT-Licensing to San Francisco Quince Therapeutics, focused on acquiring www, developing, and commercializing innovative therapeutics that transform the lives of patients suffering from debilitating and rare diseases! Immedica obtained exclusive commercialization rights in Europe and several Middle Eastern countries from in-licensing Aeglea BioTherapeutics Loargys (pegzilarginase) www. With culture at Copenhagen Denmark CDMO AGC Biologics, Rius Medical OUT-Licensing to Sweden Immedica is an option.

Out-Licensing the therapeutics enables Rius Medical to focus on enterprise AI and industrial technology for on-time-delivery to patients.

Is it a ridiculous idea for a partnership that brings enterprise AI in providing advanced therapies to patients?